Subcutaneous malignant melanoma of the scalp surgical flap after brain irradiation for anaplastic astrocytoma

Sturiale, Carmelo Lucio; Sabatino, Giovanni; Albanese, Alessio; Boccadoro, Mario; Lauriola, Libero; Pennacchia, Ilaria; Maira, Giulio

doi:10.1007/s11060-011-0646-x

Cited by 2 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, both patients developed melanoma on their head after radiotherapy for astrocytoma, thus adding to other evidence suggesting association of melanoma with exposure to ionizing radiation [28-32]; in addition, the TS of patient A, who was not treated for NST, did not develop melanoma, although she carried an identical 9p21.3 deletion (see Additional file 6: Figure S3). It results that young cancer patients treated with radiotherapy should be considered at risk for developing melanoma and their pigmented lesions should be carefully monitored by expert clinicians.…”

Section: Discussionmentioning

confidence: 54%

A large de novo9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma

et al. 2014

View full text Add to dashboard Cite

BackgroundAssociation of melanoma, neural system tumors and germ line mutations at the 9p21 region in the CDKN2A, CDKN2B and CDKN2BAS genes has been reported in a small number of families worldwide and described as a discrete syndrome in melanoma families registered as a rare disease, the melanoma–astrocytoma syndrome.Case presentationWe here studied two young patients developing melanoma after radiotherapy for astrocytoma, both reporting lack of family history for melanoma or neural system tumors at genetic counselling. Patient A is a girl treated for anaplastic astrocytoma at 10 years and for multiple melanomas on the scalp associated to dysplastic nevi two years later. Her monozygotic twin sister carried dysplastic nevi and a slow growing, untreated cerebral lesion. Direct sequencing analysis showed no alterations in melanoma susceptibility genes including CDKN2A, CDK4, MC1R and MITF or in TP53. By microsatellite analysis, multiplex ligation-dependent probe amplification, and array comparative genomic hybridization a deletion including the CDKN2A, CDKN2B and CDKN2BAS gene cluster was detected in both twin sisters, encompassing a large region at 9p21.3 and occurring de novo after the loss of one paternal allele.Patient B is a boy of 7 years when treated for astrocytoma then developing melanoma associated to congenital nevi on the head 10 years later: sequencing and multiplex ligation-dependent probe amplification revealed a normal profile of the CDKN2A/CDKN2B/CDKN2BAS region. Array comparative genomic hybridization confirmed the absence of deletions at 9p21.3 and failed to reveal known pathogenic copy number variations.ConclusionsBy comparison with the other germ line deletions at the CDKN2A, CDKN2B and CDKN2BAS gene cluster reported in melanoma susceptible families, the deletion detected in the two sisters is peculiar for its de novo origin and for its extension, as it represents the largest constitutive deletion at 9p21.3 region identified so far.In addition, the two studied cases add to other evidence indicating association of melanoma with exposure to ionizing radiation and with second neoplasm after childhood cancer. Melanoma should be considered in the monitoring of pigmented lesions in young cancer patients.

show abstract

Section: Discussionmentioning

confidence: 54%

A large de novo9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma

et al. 2014

View full text Add to dashboard Cite

show abstract

The expression of Wnt-1 inducible signaling pathway protein-2 in astrocytoma: Correlation between pathological grade and clinical outcome

Xiao¹,

Tang

Yuan³

et al. 2014

Oncology Letters

View full text Add to dashboard Cite

Wnt-1 inducible signaling pathway protein-2 (WISP-2) is a member of the CCN family, which is critical for the control of cell morphology, motion, adhesion and other processes involved in tumorigenesis. The expression pattern and clinical significance of WISP-2 in astrocytomas remains unclear. In this study, reverse transcription-polymerase chain reaction was performed to systematically investigate the expression of WISP-2 in 47 astrocytoma tissues of different pathological grades and 10 normal brain tissues. The mRNA expression levels of WISP-2 in the astrocytoma tissues were observed to be significantly higher than those in the normal brain tissues. Furthermore, the upregulation of WISP-2 was found to be associated with astrocytomas of higher pathological grades. Subsequently, 154 astrocytoma and 15 normal brain tissues were analyzed using immunohistochemistry and similar results were obtained. Univariate and multivariate survival analyses were used to determine the correlations between WISP-2 expression and overall survival (OS) and progression-free survival (PFS). The results indicated that the expression of WISP-2 was found to negatively correlate with patient PFS and OS. These results demonstrated that the WISP-2 protein is involved in the pathogenesis and progression of human astrocytomas and may serve as a malignant biomarker of this disease.

show abstract

Subcutaneous malignant melanoma of the scalp surgical flap after brain irradiation for anaplastic astrocytoma

Cited by 2 publications

References 43 publications

A large de novo9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma

A large de novo9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma

The expression of Wnt-1 inducible signaling pathway protein-2 in astrocytoma: Correlation between pathological grade and clinical outcome

Contact Info

Product

Resources

About